Diabetic Autonomic Neuropathy

Seminars in Neurology

Volumn 23, Issue 4, 2003, Pages 365-372

  Vinik, Aaron I ^a   Freeman, Roy ^b   Erbas, Tomris ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Autonomic neuropathy; Cardiovascular autonomic neuropathy; Diabetes mellitus; Erectile dysfunction; Gastrointestinal autonomic neuropathy; Neurogenic bladder

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIBIOTIC AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETHANECHOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; COLESTYRAMINE; DOMPERIDONE; DOXAZOSIN; ERYTHROMYCIN; FLUDROCORTISONE; HYDROCORTISONE DERIVATIVE; METOCLOPRAMIDE; METRONIDAZOLE; PANCREAS ENZYME; PAPAVERINE; PHENTOLAMINE; PROKINETIC AGENT; PROPANTHELINE BROMIDE; PROSTAGLANDIN E1; SCOPOLAMINE; SILDENAFIL; SOMATOSTATIN DERIVATIVE; SULPIRIDE; TADALAFIL; THIOCTIC ACID; TRIHEXYPHENIDYL; VARDENAFIL;

AUTOIMMUNE DISEASE; AUTONOMIC NERVOUS SYSTEM; AUTONOMIC NEUROPATHY; CLINICAL FEATURE; CONFERENCE PAPER; CONSTIPATION; DIABETES MELLITUS; DIABETIC NEUROPATHY; ERECTILE DYSFUNCTION; GROWTH REGULATION; HEALTH CARE COST; HUMAN; HYPERHIDROSIS; MORBIDITY; MORTALITY; NERVE REGENERATION; NEUROGENIC BLADDER; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SKIN BLOOD FLOW; URINE RETENTION; XEROSTOMIA;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEUROPATHIES; HUMANS; MALE;

EID: 1842511799     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-817720     Document Type: Conference Paper

References (55)

1. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553-1579
2. Freeman R. Diabetic autonomic neuropathy: an overview. In: Veves A, ed. Clinical Management of Diabetic Neuropathy. Totowa, NJ: Humana Press; 1998:181-208
3. Vinik AI, Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med 2001;68:928-944
4. Vinik AI, Erbas T, Pfeifer MA, Feldman EL, Stevens MJ, Russell JW. Diabetic autonomic neuropathy. In: Porte D, Sherwin RS, Baron A, eds. Ellenberg & Rifkin's Diabetes Mellitus. 6th ed. New York: McGraw Hill; 2003:789-804
5. Ewing DJ, Clarke BF. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care 1986;9:648-665
6. Ziegler D. Cardiovascular autonomic neuropathy: clinical manifestations and measurement. Diabetes Reviews 1999;7:300-315
7. Pfeifer MA, Weinberg CR, Cook DL, et al. Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care 1984;7:447-453
8. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-824
9. Neil HA, Thompson AV, John S, McCarthy ST, Mann JI. Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population. Diabet Med 1989;6:20-24
10. Ziegler D, Gries FA, Spuler M, Lessmann F. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group: the epidemiology of diabetic neuropathy. J Diabetes Complications 1992;6:49-57
11. Greene DA, Lattimer SA, Sima AA. Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes 1988;37:688-693
12. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997;46(S2):S31-S37
13. Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997;46(suppl 2):S38-S42
14. Hoeldtke RD, Bryner KD, McNeill DR, et al. Nitrosative stress, uric acid, and peripheral nerve function in early type 1 diabetes. Diabetes 2002;51:2817-2825
15. Vinik AI, Erbas T, Tae S, Stansberry K, Scanelli JA, Pittenger GL. Dermal neurovascular dysfunction in type 2 diabetes. Diabetes Care 2001;24:1468-1475
16. Pittenger GL, Malik RA, Burcus N, Boulton AJ, Vinik AI. Specific fiber deficits in sensorimotor diabetic polyneuropathy correspond to cytotoxicity against neuroblastoma cells of sera from patients with diabetes. Diabetes Care 1999;22:1839-1844
17. Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994;634:7-12
18. Horrobin DF. Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes 1997;46(suppl 2):S90-S93
19. Vincenti AM, Brownlee M, Russell JW. Oxidative stress and programmed cell death in diabetic neuropathy. Ann N Y Acad Sci 2002;959:368-383
20. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 2002;51:514-521
21. Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003;112:1049-1057
22. Ziegler D, Gries FA, Muhlen H, Rathmann W, Spuler M, Lessmann F. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes center. The DiaCAN Multicenter Study Group. Diabetes Metab 1993;19:143-151
23. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003;26:1895-1901
24. Kahn J, Zola B, Juni J, Vinik AI. Decreased exercise heart rate in diabetic subjects with cardiac autonomic neuropathy. Diabetes Care 1986;9:389-394
25. Ewing DJ, Boland O, Neilson JM, Cho CG, Clarke BF. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 1991;34:182-185
26. Valensi P, Sachs RN, Harfouche B, et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care 2001;24:339-343
27. Milan Study on Atherosclerosis and Diabetes. (MiSAD) Group: prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Am J Cardiol 1997;79:134-139
28. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction: The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998;21:69-75
29. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985;8:491-498
30. Freeman R, Saul P, Roberts M, Berger RD, Broadbridge C, Cohen R. Spectral analysis of heart rate in diabetic autonomic neuropathy. Arch Neurol 1991;48:185-190
31. Risk M, Bril V, Broadbridge C, Cohen A. Heart rate variability measurement in diabetic neuropathy: review of methods. Diabetes Technol Ther 2001;3:63-76
32. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996;93:1043-1065
33. Kilo S, Berghoff M, Hilz M, Freeman R. Neural and endothelial control of the microcirculation in diabetic peripheral neuropathy. Neurology 2000;54:1246-1252
34. Stansberry KB, Hill MA, Shapiro SA, McNitt PM, Bhatt BA, Vinik AI. Impairment of peripheral blood flow responses in diabetes resembles an enhanced aging effect. Diabetes Care 1997;20:1711-1716
35. Stansberry KB, Peppard HR, Babyak LM, Popp G, McNitt PM, Vinik AI. Primary nociceptive afferents mediate the blood flow dysfunction in non-glabrous (hairy) skin of type 2 diabetes: a new model for the pathogenesis of microvascular dysfunction. Diabetes Care 1999;22:1549-1554
36. Vinik AI, Erbas T, Park TS, Pierce KK, Stansberry KB. Methods for evaluation of peripheral neurovascular dysfunction. Diabetes Technol Ther 2001;3:29-50
37. Maleki D, Locke GR III, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000;160:2808-2816
38. Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE. Natural history of diabetic gastroparesis. Diabetes Care 1999;22:503-507
39. Vinik A, Erbas T, Stansberry K. Gastrointestinal, genitourinary, and neurovascular disturbances in diabetes. Diabetes Reviews 1999;7:358-378
40. Lysy J, Israeli E, Goldin E. The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol 1999;94:2165-2170
41. Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002;25:1458-1463
42. Richardson D, Vinik A. Etiology and treatment of erectile failure in diabetes mellitus. Curr Diab Rep 2002;2:501-509
43. Bradley WE. Diagnosis of urinary bladder dysfunction in diabetes mellitus. Ann Intern Med 1980;92:323-326
44. Shaw JE, Parker R, Hollis S, Gokal R, Boulton AJ. Gustatory sweating in diabetes mellitus. Diabet Med 1996;13:1033-1037
45. Cryer PE. Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol Endocrinol Metab 2001;281:E1115-E1121
46. DCCT Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998;41:416-423
47. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-622
48. Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999;107:421-430
49. Ebbehoj E, Poulsen PL, Hansen KW, Knudsen ST, Molgaard H, Mogensen CE. Effects on heart rate variability of metoprolol supplementary to on going ACE-inhibitor treatment in type I diabetic patients with abnormal albuminuria. Diabetologia 2002;45:965-975
50. Kontopoulos AG, Athyros VG, Didangelos TP, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997;20:355-361
51. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352:1978-1981
52. Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993;16:1511-1514
53. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990;322:1028-1031
54. Shaw JE, Abbott CA, Tindle K, Hollis S, Boulton AJ. A randomized controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating. Diabetologia 1997;40:299-301
55. Restivo DA, Lanza S, Patti F, et al. Improvement of diabetic autonomic gustatory sweating by botulinum toxin type A. Neurology 2002;59:1971-1973